Deadly genetic heart condition leads Sanofi to $200M MyoKardia deal
September 17, 2014 at 01:38 AM EDT
Startup MyoKardia Inc.’s focus on treatments for deadly genetic heart diseases has landed a potential $200 million collaboration with French drug maker Sanofi...